Clinical Trials Logo

Clinical Trial Summary

Agitation in the intensive care unit is motor hyperactivity. It is frequent (b/w 30% to 70%) and has multiple causes: pain, medical reason, delirium, medication, etc. It can be a source of complication, for the patient, and equipment pullout. International recommendations state that the agitation should be taken care of with standardized protocols to improve patient care.


Clinical Trial Description

Data regarding patient characteristics and evaluation criterion will be collected automatically with the unit software (CCC, General Electrics) in specific file. Care and health teams enter the data systematically following the usual protocol. First Step : Follow-up and collection of data of patients included. Agitation evaluation with RASS scale, pain evaluation with BPS or NPRS. Second Step: Team training to delirium evaluation scale (CAM-ICU) and to the use of care algorithm. Third Step: Follow-up and collection of data of patients included. Use of care algorithm by doctors, nurses and back up training nurse to ensure daily information to health professionals of the care unit. Concomitant Step: Post discharge from care unit medical appointment to evaluate anxiety symptoms (HAD scale) and quality of life (SF-12) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04053426
Study type Observational
Source University Hospital, Grenoble
Contact
Status Completed
Phase
Start date July 19, 2018
Completion date March 31, 2021

See also
  Status Clinical Trial Phase
Terminated NCT03110900 - Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation Phase 4
Completed NCT05272501 - CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility Trial N/A
Completed NCT06041646 - Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder Phase 4
Completed NCT06217146 - A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia. N/A
Recruiting NCT05543681 - IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's Phase 2
Recruiting NCT03513549 - Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3
Not yet recruiting NCT05612711 - Dronabinol for Agitation in Dementia Crossover Trial Phase 2
Recruiting NCT04957238 - Physical Restraints in Intensive Care Unit Patients N/A
Completed NCT03208452 - The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation Phase 4
Terminated NCT03899506 - Olanzapine Versus Midazolam for Agitation
Completed NCT03211897 - Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation N/A
Recruiting NCT05783505 - A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use N/A
Completed NCT03226522 - Addressing Dementia Via Agitation-Centered Evaluation Phase 2/Phase 3
Recruiting NCT03926520 - Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) N/A
Recruiting NCT04075435 - Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia Early Phase 1
Completed NCT04276883 - Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder Phase 3
Completed NCT04797715 - Assessing Clinical Outcomes in Alzheimer's Disease Agitation Phase 3
Completed NCT04251910 - Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia Phase 1/Phase 2
Recruiting NCT05765162 - Safe Brain Initiative, Operationalizing Precision Anaesthesia